In a nutshell This study summarized findings on the treatment combination known as CRd (carfilzomib [Kyprolis], lenalidomide [Revlimid], and dexamethasone [Decadron]) for previously treated multiple myeloma. The study concluded that CRd is superior in improving progression and treatment response rates compared to available alternatives. Some...
Read MoreMultiple Myeloma Posts on Medivizor
Carfilzomib improves outcome in patients with refractory multiple myeloma
In a nutshell This paper studied the use of carfilzomib (Kyprolis) in high-risk patients with multiple myeloma. This study concluded that carfilzomib improved survival and response to treatment. Some background Multiple myeloma is a cancer of the plasma cells (type of white blood cell). Following treatment, many patients relapse (have a...
Read MoreTreatment combinations for multiple myeloma patients with the 17p deletion
In a nutshell This study analyzed the results of 13 separate studies on treatment combinations for multiple myeloma patients with the 17p deletion. This study concluded that bortezomib-based primary and maintenance therapy improved outcomes in newly diagnosed patients with the 17p deletion. The combination...
Read MoreUsing erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation
In a nutshell This study looked at how effective erythropoietin mouthwash was at preventing oral mucositis in cancer patients being treated with autologous stem cell transplantation. The study concluded that rinsing with erythropoietin mouthwash can prevent oral mucositis. Some background Oral mucositis (OM) is a complication associated with...
Read MoreManaging high-risk multiple myeloma
In a nutshell This study reviewed evidence on the management of high-risk multiple myeloma. Some background Multiple myeloma is a diverse disease. Using predictors of treatment success is important to help select treatment approaches for patients. Higher risk patients may benefit from more aggressive treatment. There are multiple methods...
Read MoreHow anxiety, depression, and unmet patient needs impact the quality of life of patients with multiple myeloma
In a nutshell This study looked at how anxiety and depression influence the quality of life of patients with multiple myeloma. The study concluded that anxiety, depression, and unmet patient needs negatively impact the physical and emotional well-being of patients. Some background Multiple myeloma is a common type of cancer in older adults. The...
Read MoreCarfilzomib versus bortezomib in multiple myeloma that has not responded to treatment
In a nutshell This paper compared the use of carfilzomib (Kyprolis) and bortezomib (Velcade) in the treatment of multiple myeloma. This study concluded that carfilzomib was associated with a reduced risk of death compared with bortezomib. Some background Multiple myeloma is a cancer of the plasma cells. New treatments have led to longer survival...
Read MoreCan Video Gaming Build Resilience? You Decide…
In the aftermath of Hurricanes Harvey and Irma, a recent news story discussed the mental health consequences of disasters. Researcher Jean Rhodes of University of Massachusetts Boston studied the mental health of young parents living in New Orleans before and after Hurricane Katrina. RISK- Resilience In Survivors of Katrina is the project’s name. An...
Read MoreIs There a Difference in Treatment in Smoldering vs. Active Myeloma?
In this Patient Power replay, an expert panel discusses the differences in treatment between smoldering and active myeloma. The expert panel includes Host Andrew Schorr, Dr. Larry Anderson, Jr. of UT Southwest Medical Center, Dr. Robert Orlowski of MD Anderson Cancer Center, and patient advocate Lynette Heniff. In this video, the panel discusses risk...
Read MoreTreatment options and combinations for multiple myeloma
In a nutshell The aim of this study was to review current treatment options and combinations for multiple myeloma. Some background Advances in first-line treatments have improved response and survival rates among multiple myeloma patients. In recent years immunotherapies and targeted therapies have become a major treatment option....
Read MoreExamining infection rates after stem cell transplantation
In a nutshell This study examined infection rates after autologous stem cell transplantation in multiple myeloma patients. 1.2% in-hospital deaths were recorded in this study. All were caused by an infection following the stem cell transplant. Some background Autologous stem cell transplantation after high-dose chemotherapy has resulted in...
Read MoreA look at frailty in elderly multiple myeloma patients
In a nutshell This study reviewed evidence on how to categorize older multiple myeloma patients. Some background Advances in treatment approaches have improved response rates and survival for multiple myeloma patients. These typically involve combining immunotherapies, such as lenalidomide (Revlimid), with proteasome inhibitors, such as bortezomib...
Read More
